Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Research Triangle Park, NC, USA and Cambridge, UK, 11 January 2022 -- Inivata, a leader...

Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe ...

Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer Research Collaboration to be led by the University of Southampton and along with...

Inivata to Present Data at AACR Virtual Annual Meeting Highlighting Capabilities and Clinical Application of RaDaR™ Assay Inivata to Present Data at AACR Virtual Annual Meeting Highlighting Capabilities and Clinical Application of RaDaR™ Assay Personalized assay for detection of residual disease and recurrence...